15 Facts About COVID

Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, loss of smell, and loss of taste.

Symptoms of COVID-19 are variable depending on the type of variant contracted, ranging from mild symptoms to critical and possibly fatal illness.

COVID-19 is caused by infection with a strain of coronavirus known as 'Severe Acute Respiratory Syndrome coronavirus 2' .

COVID-19 is most known for affecting the upper respiratory tract and the lower respiratory tract .

The involvement of both the central and peripheral nervous system in COVID-19 has been reported in many medical publications.

Related searches

Autopsies of people who died of COVID-19 have found diffuse alveolar damage, and lymphocyte-containing inflammatory infiltrates within the lung.

Unvaccinated women in later stages of pregnancy with COVID-19 are more likely than other patients to need very intensive care.

Evidence indicates that contact with infected surfaces is not the main driver of COVID-19, leading to recommendations for optimised disinfection procedures to avoid issues such as the increase of antimicrobial resistance through the use of inappropriate cleaning products and processes.

The cornerstone of management of COVID-19 has been supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support and prone positioning as needed, and medications or devices to support other affected vital organs.

Abnormal sodium levels during hospitalization with COVID-19 are associated with poor prognoses: high sodium with a greater risk of death, and low sodium with an increased chance of needing ventilator support.

Key metric in gauging the severity of COVID-19 is the infection fatality rate, referred to as the infection fatality ratio or infection fatality risk.

International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers.

Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19, retrofits of crowd movement models to study occupant exposure, mobility-data based models to investigate transmission, or the use of macroeconomic models to assess the economic impact of the pandemic.

Data collected from Jin Yin-tan Hospital in Wuhan, China indicates that patients who had more severe responses to COVID-19 had greater amounts of pro-inflammatory cytokines and chemokines in their system than patients who had milder responses.

The interleukin-6 receptor antagonist was approved by the FDA to undergo a PhaseIII clinical trial assessing its effectiveness on COVID-19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.